J
Juan E. Grunwald
Researcher at University of Pennsylvania
Publications - 187
Citations - 16851
Juan E. Grunwald is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Macular degeneration & Retinopathy. The author has an hindex of 63, co-authored 184 publications receiving 15007 citations. Previous affiliations of Juan E. Grunwald include Johns Hopkins University & Scheie Eye Institute.
Papers
More filters
Journal ArticleDOI
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F. Martin,Maureen G. Maguire,Gui-Shuang Ying,Juan E. Grunwald,Stuart L. Fine,Glenn J. Jaffe +5 more
TL;DR: Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizuab administered monthly, although the comparison between bevacizumAB as needed and monthly bevicizumabs was inconclusive.
Journal ArticleDOI
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F. Martin,Maureen G. Maguire,Stuart L. Fine,Gui-Shuang Ying,Glenn J. Jaffe,Juan E. Grunwald,Cynthia A. Toth,Maryann Redford,Frederick L. Ferris +8 more
TL;DR: Ranibizumab and bevacizumAB had similar effects on visual acuity over a 2-year period and switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2.
Journal ArticleDOI
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Juan E. Grunwald,Ebenezer Daniel,Jiayan Huang,Gui-Shuang Ying,Maureen G. Maguire,Cynthia A. Toth,Glenn J. Jaffe,Stuart L. Fine,Barbara A Blodi,Michael L. Klein,Alison Martin,Stephanie A. Hagstrom,Daniel F. Martin +12 more
TL;DR: Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography were evaluated as risk factors for GA through 2 years of follow-up and found no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.
Journal ArticleDOI
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire,Daniel F. Martin,Gui-Shuang Ying,Glenn J. Jaffe,Ebenezer Daniel,Juan E. Grunwald,Cynthia A. Toth,Frederick L. Ferris,Stuart L. Fine +8 more
TL;DR: Vision gains during the first 2 years were not maintained, but 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.
Journal Article
Blood velocity and volumetric flow rate in human retinal vessels.
TL;DR: Blood velocity in the major retinal vessels measured under normal experimental conditions appears remarkably constant over short (hours) and long (months) periods of time.